Continuing GDMT or Starting a Palliative Inotrope in End-Stage Heart Failure Hospice
A grandfather enrolled in home hospice for end-stage heart failure is fading despite a guideline-perfect medication regimen, and his family is asking about a continuous inotrope infusion they read about online — a drug with real arrhythmia risk that the team still has to weigh honestly against what it might actually buy him.
A.G.'s three grandchildren wait in the hallway during his family meeting because they've asked to visit as soon as the clinicians leave, an arrangement that has become the rhythm of his third week in home hospice for end-stage heart failure. He remains on the full four pillars of guideline-directed medical therapy — carvedilol, sacubitril-valsartan, spironolactone, dapagliflozin — the same regimen that kept him functional for years before his ejection fraction dropped to 14% and hospice became the honest next step. His daughter found an article about continuous home inotrope infusions and has asked directly whether milrinone could buy her father more comfortable time, a question the team owes a straight answer rather than a reflexive no.
Continuous inotrope infusion in end-stage heart failure carries a real, well-documented downside. OPTIME-CHF, the largest randomized test of short-term intravenous milrinone, put numbers on it: no reduction in hospital days at sixty days, sustained hypotension requiring intervention in 10.7% against 3.2% on placebo, and new atrial arrhythmias in 4.6% against 1.5%. Whether that verdict reaches A.G. is the whole question, and the answer is that it doesn't reach him cleanly. OPTIME-CHF enrolled patients hospitalized with a decompensation for whom inotropes were explicitly not considered essential, measured against an endpoint — days out of hospital — that presumes survival is what the drug is for. A.G. is not being decompensated back toward discharge; he is enrolled in hospice, and the endpoint his family is asking about is whether he is awake in the hallway. The arrhythmia risk doesn't disappear because the goal changed, but the calculus around accepting it changes considerably once the alternative being weighed against it isn't survival, it's whether he's alert enough for those hallway visits.
The three grandchildren waiting outside are ages five, eight, and eleven, old enough that the eldest asked her mother directly last week whether Grandpa would remember her birthday next month, a question nobody in the family has had a good answer for yet. That question is, in its own way, exactly what the family meeting is trying to answer with pharmacology instead of a promise — not whether A.G. will recover, which nobody in the room is claiming, but whether the next several weeks can include more of the alert, present time that made the hallway visits worth waiting for in the first place.
At the family meeting, with three grandchildren waiting outside
I'd start simplifying rather than adding anything. His ejection fraction has dropped from 28 to 14 in three weeks, his creatinine is climbing, and several of the four pillars he's on were built for a mortality benefit measured in years he doesn't have left. The beta-blocker and the SGLT2 inhibitor in particular carry real hemodynamic and volume effects that could be working against comfort right now rather than for it.
I don't disagree that simplification deserves real consideration, but I don't think it answers his daughter's actual question, which was about milrinone specifically. The acute-heart-failure trial literature on inotropes — the harm signal you're implicitly weighing against this — was studying inotropes as a bridge toward recovery or transplant. That's a different population and a different question than palliative inotrope use in a hospice patient whose goal is explicitly comfort and alertness, not survival. Real home-hospice practice supports that use case even though it's thinner evidence than a randomized trial.
I think the actual disagreement here is smaller than it looks — neither of you is wrong about the pharmacology, you're weighing different parts of a genuinely uncertain tradeoff. Before either of you settles this, there's a dosing constraint that has to be on the table: milrinone is eighty to ninety percent renally excreted, and his eGFR is 34 and falling. The label carries its own reduced-infusion table for exactly this creatinine-clearance range, and Cox and colleagues measured the consequence of ignoring it — steady-state plasma milrinone climbs as clearance drops in stage D heart failure, and the arrhythmia risk you're both weighting tracks that concentration. A standard-rate infusion in him isn't the same drug exposure it would be in a patient with normal kidneys. If we do this, it starts at a renally-adjusted rate. What I also want to make sure happens either way is that his daughter hears the arrhythmia risk stated plainly as a real cost, not as a footnote to a hopeful answer. If the family, with that risk understood clearly, wants to try a time-limited milrinone trial specifically for alertness during visits, that's a legitimate choice for them to make. If they'd rather focus on simplifying his regimen for comfort instead, that's equally legitimate. I don't think this decision should be made for them by whichever of you speaks first.
Agreed, after the arrhythmia risk was stated to the family in plain terms: a 72-hour trial of continuous milrinone specifically for alertness, started at a renally-adjusted infusion rate rather than a standard one given his eGFR of 34, dapagliflozin discontinued, carvedilol dose reduced rather than stopped, with the family understanding this was a time-limited trial to be reassessed, not a new standing regimen.
Not fully agreed: the Cardiologist remained more inclined toward simplification alone and said so directly, noting he would have recommended against the inotrope trial if the decision had been left entirely to clinical judgment rather than informed family choice. The Palliative Care Physician held that the family's informed choice, once the risk was named honestly, was the right basis for this specific decision.